🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Cue Biopharma hits 52-week low, trading at 0.681 USD

Published 07/25/2024, 09:36 AM
CUE
-

Cue Biopharma (NASDAQ:CUE), a leading player in the biopharmaceutical industry, has recently hit a 52-week low, with its shares trading at a mere 0.681 USD. This marks a significant downturn for the company, which has been grappling with a challenging market environment. Over the past year, Cue Biopharma's stock has seen a drastic decline, with the 1-year change data revealing a substantial drop of -81.64%. This downward trend underscores the volatility and uncertainty that currently characterizes the biopharmaceutical sector, and raises questions about the company's future performance.

InvestingPro Insights

In light of Cue Biopharma's recent challenges, InvestingPro data provides a more granular look into the company's financial health and market performance. With a market capitalization of just 36M USD, the company's size remains relatively small within the biopharmaceutical industry. Despite a striking revenue growth of 1525.0% over the last twelve months as of Q1 2024, the company's gross profit margin stands at a concerning -454.2%, indicating significant costs outweighing revenue. Moreover, the price of Cue Biopharma's stock has been on a steep downtrend, with a 1-week price total return of -15.98% and a 1-month price total return of -51.83%, reflecting investor sentiment and market reactions to the company's performance and outlook.

InvestingPro Tips highlight a few critical aspects: Cue Biopharma holds more cash than debt on its balance sheet, which could provide some financial stability in these turbulent times. Additionally, analysts anticipate sales growth in the current year, suggesting potential for recovery. However, the stock's volatility, as indicated by the recent price drops, and the lack of profitability over the last twelve months paint a cautionary picture. For investors looking for more insights, there are additional InvestingPro Tips available, which could help in making a more informed decision. To access these tips and dive deeper into Cue Biopharma's analytics, visit https://www.investing.com/pro/CUE. Don't forget to use the coupon code PRONEWS24 to get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.